Targeted Cancer Therapy with Enhanced Conjugate Delivery

This next-generation technology combines a conjugate of formula (I) with advanced targeting moieties, companion diagnostics, and biomarker monitoring to create a more effective and personalized cancer treatment.

The original patent disclosed anti-CD25 antibody-maytansine conjugates, but these may have limited efficacy and specificity in certain cancer patients. The new inventive concept addresses these limitations by introducing nucleic acid aptamers, CD25-binding peptides, and microfluidic reactors to enhance conjugate delivery, targeting, and monitoring.

The inventive concept comprises a conjugate of formula (I) linked to a targeting moiety, such as a nucleic acid aptamer specific for a cancer cell surface receptor. This conjugate is administered in combination with a companion diagnostic test for detecting CD25 expression levels in the patient. The conjugate may also be linked to a CD25-binding peptide, which is attached to a polymer backbone. A microfluidic reactor is used to prepare the conjugate, and a sensor monitors the conjugation reaction. The treatment's efficacy is monitored by measuring biomarker levels in patient samples and adjusting the treatment regimen accordingly.

The new claims introduce a paradigm shift in targeted cancer therapy by combining the conjugate of formula (I) with advanced targeting moieties, companion diagnostics, and biomarker monitoring. This integration of components provides a more effective and personalized treatment approach, making the original inventive concept obsolete.

Alternative embodiments of the inventive concept could include using different targeting moieties, such as nanoparticles or liposomes, or varying the conjugate's formula to target different cancer cell receptors. The microfluidic reactor could be replaced with other conjugation methods, and the biomarker monitoring could be performed using different detection techniques.

The targeted cancer therapy with enhanced conjugate delivery has significant commercial potential in the oncology market, particularly for treating aggressive and hard-to-treat cancers. The market for cancer therapies is expected to grow significantly in the coming years, and this inventive concept is well-positioned to capture a share of that market.